HomeCompareSUEZY vs ABBV

SUEZY vs ABBV: Dividend Comparison 2026

SUEZY yields 2.11% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SUEZY wins by $80.38M in total portfolio value· pulled ahead in Year 4
10 years
SUEZY
SUEZY
● Live price
2.11%
Share price
$5.70
Annual div
$0.12
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.48M
Annual income
$73,753,617.92
Full SUEZY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SUEZY vs ABBV

📍 SUEZY pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSUEZYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SUEZY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SUEZY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SUEZY
Annual income on $10K today (after 15% tax)
$179.10/yr
After 10yr DRIP, annual income (after tax)
$62,690,575.23/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SUEZY beats the other by $62,669,519.23/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SUEZY + ABBV for your $10,000?

SUEZY: 50%ABBV: 50%
100% ABBV50/50100% SUEZY
Portfolio after 10yr
$40.29M
Annual income
$36,889,194.84/yr
Blended yield
91.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SUEZY
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
2.2
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SUEZY buys
0
ABBV buys
0
No recent congressional trades found for SUEZY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSUEZYABBV
Forward yield2.11%3.06%
Annual dividend / share$0.12$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$80.48M$102.3K
Annual income after 10y$73,753,617.92$24,771.77
Total dividends collected$79.94M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: SUEZY vs ABBV ($10,000, DRIP)

YearSUEZY PortfolioSUEZY Income/yrABBV PortfolioABBV Income/yrGap
1$11,121$421.42$11,550$430.00$429.00ABBV
2$12,776$876.04$13,472$627.96$696.00ABBV
3$15,551$1,881.06$15,906$926.08$355.00ABBV
4← crossover$20,920$4,279.81$19,071$1,382.55+$1.8KSUEZY
5$33,145$10,761.15$23,302$2,095.81+$9.8KSUEZY
6$67,335$31,869.13$29,150$3,237.93+$38.2KSUEZY
7$193,061$121,013.26$37,536$5,121.41+$155.5KSUEZY
8$855,115$648,539.13$50,079$8,338.38+$805.0KSUEZY
9$6,284,198$5,369,225.20$69,753$14,065.80+$6.21MSUEZY
10$80,477,710$73,753,617.92$102,337$24,771.77+$80.38MSUEZY

SUEZY vs ABBV: Complete Analysis 2026

SUEZYStock

Südzucker AG produces and sells sugar products in Germany and internationally. It operates through five segments: Sugar, Special Products, CropEnergies, Starch, and Fruit. The Sugar segment produces and sells sugar, sugar specialty products, glucose syrup, and animal feed to food industry, retailers, and agriculture markets, as well as offers by-products of sugar. The Special Products segment produces functional food ingredients, including dietary fibers, sugar substitutes, sugar, rice starches/flours, and functionalized wheat protein for food, animal feed, non-food, and pharmaceutical industries. This segment also offers frozen and chilled pizzas, pasta, baguette, and sauces and dressings; and portion packed foods and non-food products to hotels, caterers, food retailers, and restaurants. The CropEnergies segment produces fuel-grade ethanol, rectified spirits, protein-based food and animal feed, and liquid CO2 to oil companies and traders, industrial and pharmaceutical companies, food and animal feed producers, and beverage and cosmetics producers. The Starch segment offers starches, saccharification products, ethanol, and byproducts which includes animal feed and fertilizers to food, paper, textiles, industrial chemicals, pharmaceuticals, cosmetics, petroleum, and animal feed industries. The Fruit segment produces fruit preparations for the dairy, ice cream, baked goods, and food service industries; and fruit juice concentrates, pure juices, fruit wines, natural aromas, and beverage bases for beverage industry. It is also involved in agricultural activities; and cultivation of wheat, sugar beet, corn, chicory, rapeseed, soybean, and other products. The company was founded in 1837 and is headquartered in Mannheim, Germany. Südzucker AG is a subsidiary of Süddeutsche Zuckerrübenverwertungs-Genossenschaft eG.

Full SUEZY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SUEZY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SUEZY vs SCHDSUEZY vs JEPISUEZY vs OSUEZY vs KOSUEZY vs MAINSUEZY vs JNJSUEZY vs MRKSUEZY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.